Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin

Future Microbiology

Volumn 10, Issue 12, 2015, Pages 1901-1912

  Ehsan, Zarmina ^a   Clancy, John P ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

amikacin; arikace; arikayce; cystic fibrosis; LAI; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; COLISTIMETHATE; FOSFOMYCIN; TOBRAMYCIN; AEROSOL; ANTIINFECTIVE AGENT; DRUG CARRIER; LIPOSOME;

ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BREATHING EXERCISE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FIBROSIS; NEBULIZATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; AEROSOL; COMPLICATION; CYSTIC FIBROSIS; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; AEROSOLS; AMIKACIN; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG CARRIERS; HUMANS; LIPOSOMES; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84948394280     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.117     Document Type: Article

References (80)

1. Ramsey BW, Dorkin HL, Eisenberg JD et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328(24), 1740-1746 (1993).
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N. Engl. J. Med. 352(19), 1992-2001 (2005).
3. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 139(6), 1480-1490 (2011).
4. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Briemer DD. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 41(1), 184-187 (1997).
5. Steinkamp G, Tummler B, Gappa M et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr. Pulmon. 6(2), 91-98 (1989).
6. Mogayzel PJ, Jr., Naureckas ET, Robinson KA et al. Cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann. Am. Thorac. Soc. 11(10), 1640-1650 (2014).
7. Tiddens HA, Bos AC, Mouton JW, Devadason S, Janssens HM. Inhaled antibiotics: dry or wet Eur. Respir. J. 44(5), 1308-1318 (2014).
8. Doring G, Flume P, Heijerman H, Elborn JS. Consensus Study G. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cystic Fibrosis 11(6), 461-479 (2012).
9. Cystic Fibrosis Foundation Patient Registry Annual Data Report. 2015 (9 June 2015). (2013).
10. Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J. Cystic Fibrosis 8(6), 361-369 (2009).
11. Zhao J, Schloss PD, Kalikin LM et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc. Natl Acad. Sci. USA 109(15),5809-5814 (2012).
12. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288(5469), 1251-1254 (2000).
13. Kenna DT, Doherty CJ, Foweraker J, Macaskill L, Barcus VA, Govan JR. Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology 153(Pt 6),1852-1859 (2007).
14. Ciofu O, Mandsberg LF, Wang H, Hoiby N. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunol. Med. Microbiol. 65(2), 215-225 (2012).
15. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416(6882), 740-743 (2002).
16. Hogardt M, Heesemann J. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr. Topics Microbiol. Immunol. 358 91-118 (2013).
17. Sousa AM, Pereira MO. Pseudomonas aeruginosa diversification during Infection development in cystic fibrosis lungs-a review. Pathogens 3(3), 680-703 (2014).
18. Pressler T, Bohmova C, Conway S et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J. Cystic Fibrosis 10(Suppl. 2), S75-S78 (2011).
19. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cystic Fibrosis 2(1), 29-34 (2003).
20. Schaedel C, De Monestrol I, Hjelte L et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr. Pulmon. 33(6), 483-491 (2002).
21. Flume PA, Mogayzel PJ Jr, Robinson KA et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 180(9), 802-808 (2009).
22. Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr. Pulmon. 46(9), 870-881 (2011).
23. Regelmann WE, Schechter MS, Wagener JS et al. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. Pediatr. Pulmon. 48(7), 649-657 (2013).
24. Rabin HR, Butler SM, Wohl ME et al. Pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmon. 37(5), 400-406 (2004).
25. Bilton D, Canny G, Conway S et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J. Cystic Fibrosis 10(Suppl. 2), S79-S81 (2011).
26. Maiz L, Giron RM, Olveira C et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin. Pharmacother. 14(9), 1135-1149 (2013).
27. Sanders DB, Hoffman LR, Emerson J et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr. Pulmon. 45(2), 127-134 (2010).
28. Lipuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120(3 Suppl.), 118S-123S (2001).
29. Flume PA, Vandevanter DR. Clinical applications of pulmonary delivery of antibiotics. Adv. Drug Deliv. Rev. 85, 1-6 (2015).
30. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9, 32 (2011).
31. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 165(9), 847-856 (2011).
32. Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr. Pulmon. 40(1), 39-44 (2005).
33. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J. Cystic Fibrosis 4(Suppl. 2), 49-54 (2005).
34. Taccetti G, Bianchini E, Cariani L et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 67(10), 853-859 (2012).
35. Lee TW. Eradication of early Pseudomonas infection in cystic fibrosis. Chron. Respir. Dis. 6(2), 99-107 (2009).
36. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur. Respir. J. 44(2), 382-393 (2014).
37. Ratjen F, Munck A, Kho P, Angyalosi G, Group ES. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4), 286-291 (2010).
38. Rosenfeld M, Emerson J, Mcnamara S et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J. Cystic Fibrosis 11(5), 446-453 (2012).
39. Meyer RD, Young LS, Armstrong D. Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl. Microbiol. 22(6), 1147-1151 (1971).
40. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23-30 (1999).
41. Gilligan PH. Microbiology of airway disease in patients with cystic-fibrosis. Clin. Microbiol. Rev. 4(1), 35-51 (1991).
42. Konstan MW, Flume PA, Kappler M et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cystic Fibrosis 10(1), 54-61 (2011).
43. Mazurek H, Chiron R, Kucerova T et al. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Pediatr. Pulmon. 49(11), 1076-1089 (2014).
44. Chiesi Farmaceutici s.PA. Product portfolio. 2015. (2014). http://www.chiesi.uk.com
45. Chiesi USA Inc. Bethkis (tobramycin inhalation solution): Concentrated formulation for efficient nebulization. 2015(Web page accessed April 6,2015), (2015). 6 April 2015.
46. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122(1), 219-226 (2002).
47. Smith AL, Ramsey BW, Hedges DL et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmon. 7(4), 265-271 (1989).
48. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst. Rev. 3, CD001021 (2011).
49. Sands D, Sapiejka E, Gaszczyk G, Mazurek H, Group TS. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. J. Cystic Fibrosis 13(6), 653-660 (2014).
50. CFMPFHU. European Medicine Agency Assessment report: Vantobra. (2015).
51. Mccoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(9), 921-928 (2008).
52. Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135(5), 1223-1232 (2009).
53. Oermann CM, Retsch-Bogart GZ, Quittner AL et al. An 18 month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr. Pulmon. 45(11), 1121-1134 (2010).
54. Assael BM, Pressler T, Bilton D et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J. Cystic Fibrosis doi:10.1016/j.jcf.2012.07.006 (2012).
55. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin. Microbiol. Infect. 18(1), 18-29 (2012).
56. Nation RL, Li J. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22(6), 535-543 (2009).
57. Schuster A, Haliburn C, Doring G, Goldman MH. Freedom Study G. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 68(4), 344-350 (2013).
58. Littlewood KJ, Higashi K, Jansen JP et al. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J. Cystic Fibrosis 11(5), 419-426 (2012).
59. Trapnell BC, Mccolley SA, Kissner DG et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am. J. Respir. Crit. Care Med. 185(2), 171-178 (2012).
60. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann. NY Acad. Sci. 235(0), 364-386 (1974).
61. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303(23), 2386-2392 (2010).
62. Forest Pharmaceuticals I. Forest laboratories: Product website. 2015(Date accessed October 26, 2015), (2014). (2014).
63. Geller DE, Flume PA, Griffith DC et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agent. Chemother. 55(6), 2636-2640 (2011).
64. Geller DE, Flume PA, Staab D et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 183(11), 1510-1516 (2011).
65. Aptalis Pharma I. Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsAptalis Pharma, Inc. Announces Results of Phase 3 Studies of Aeroquin™ (Levofloxacin Solution for Inhalation) Among Patients With Cystic Fibrosis and Chronic Lung Infection. NCT01270347 Study Mpex 209 and 207 (2013).
66. Young DC, Zobell JT, Stockmann C et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr. Pulmon. doi:10.1002/ppul.22813 (2013).
67. Okusanya OO, Bhavnani SM, Hammel J et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agent. Chemother. 53(9), 3847-3854 (2009).
68. Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 61(4), 859-868 (2008).
69. Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J. Aerosol Med. Pulmon. Drug Deliv. 22(2), 131-138 (2009).
70. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 11, CD004197 (2014).
71. Li Z, Zhang Y, Wurtz W et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol Med. Pulmon. Drug Deliv. 21(3), 245-254 (2008).
72. Mckeage K. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs 73(16),1815-1827 (2013).
73. Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J. Cystic Fibrosis 13(2), 172-178 (2014).
74. Doring G, Conway SP, Heijerman HG et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16(4), 749-767 (2000).
75. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst. Rev. 12, CD010004 (2012).
76. Clancy JP, Dupont L, Konstan MW et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 68(9), 818-825 (2013).
77. Bilton D, Pressler T, Fajac Iet al. Phase 3 efficacy and safety data from randomized, multicenterstudy of liposomal amikacin for inhalation (Arikace® ) compared with Tobi® incystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. Presented at: 2013 North American Cystic Fibrosis Conference (NACFC). (2013).
78. Bilton D, Pressler T, Fajac Iet al. Analysis of long-term liposomal amikacin for inhalation in patients with cysticfibrosis and chronic infection from Pseudomonas aeruginosa. Poster presented at: 2014 North American Cystic Fibrosis Conference. Atlanta, GA, USA, 9-11 October 2014.
79. Acquire Media online news brief. Arikace meets primary endpoint of non-inferiority to Tobi in Phase 3 clinical trial in Europe and Canada to treat Pseudomonas aeruginosa in cystic fibrosis patients (2013). 6 July 2015 (2013).
80. US Food and Drug Administration. Products Designating an orphan product: Drugs and biological products (2015). http://www.fda.gov